Now showing items 1-4 of 4

    • DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT 

      Jones, Rob; Sheehan, Bart; Phillips, Patrick; Juszczak, Ed; Adams, Jessica; Baldwin, Ashley; Ballard, Clive et al. (2009-07-24)
      Abstract Background Alzheimer's disease (AD) is the commonest cause of dementia. Cholinesterase inhibitors, such as donepezil, are the drug class with the best evidence of efficacy, licensed for mild to moderate AD, while ...
    • Grey matter atrophy in prodromal stage of dementia with Lewy bodies and Alzheimer's disease 

      Blanc, Frederic; Colloby, Sean J.; Cretin, Benjamin; de Sousa, Paulo Loureiro; Demuynck, Catherine; O'Brien, John T.; Martin-Hunyadi, Catherine et al. (BioMed Central, 2016)
      ${\bf Introduction:}$ Little is known about the patterns of brain atrophy inprodromal Dementia with Lewy bodies (pro-DLB). ${\bf Methods:}$ In this study, we used SPM8-DARTEL to measure gray matter (GM) volume and ...
    • Lewy bodies and neuronal loss in subcortical areas and disability in non-demented older people: a population based neuropathological cohort study 

      Byford, M.; Brayne, Carol; McKeith, Ian; Chatfield, Mark; Ince, Paul G.; Matthews, Fiona E.; MRC-CFAS (2009-06-15)
      Abstract Background Functional disability, the loss of ability to carry out daily tasks unaided, is a major adverse outcome more common with increasing age. The potential contribution of neuropathological changes in ...
    • Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis 

      Stinton, Chris; McKeith, Ian; Taylor, John-Paul; Lafortune, Louise; Mioshi, Eneida; Mak, Elijah; Cambridge, Victoria et al. (American Psychiatric Association, 2015-06-18)
      Objective: The authors examined research on effects, costs, and patient and caregiver views of pharmacological management strategies for Lewy body dementia. Method: Studies were identified through bibliographic ...